Long-Term Efficacy of Continuous Risankizumab in Psoriasis by Body Region: An Updated Integrated Analysis From the LIMMitless Open-Label...

Risankizumab Efficacy for Moderate-to-Severe Plaque Psoriasis over 256 Weeks in Patients with Prior Biologic Treatments Authors: Jeffrey...

Apremilast in Patients with Moderate-to-Severe Genital Psoriasis: Efficacy Results in the Overall Population and Body Surface Area...

Long-Term Safety of Apremilast from a Pooled Analysis of 8 Randomized, Placebo-Controlled Studies of Patients with Psoriasis Authors: L....

Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults with Chronic Plaque Psoriasis from a 52-Week, Phase 2 Open-Label...

Pooled Efficacy and Safety Results from the DERMIS-1 and DERMIS-2 Phase 3 Trials of Once-Daily Roflumilast Cream 0.3% for Treatment of...

Effisayil ON, an Open-Label, Long-Term Extension Study of Spesolimab Treatment in Patients with Generalized Pustular Psoriasis: Interim...

Spesolimab for the Prevention of Generalized Pustular Psoriasis (GPP) Flares: Results from the Randomized, Placebo-Controlled Trial...

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Evaluation of...

Deucravacitinib Long-Term Efficacy with Continuous Treatment in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program...

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: 2-Year Efficacy by...

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Evaluation of Lipid...

Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild-to-Severe...

Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild-to-Severe Plaque Psoriasis...

Real-World Effectiveness and Safety in a Phase 4 Study of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis Authors:...

Patients’ Quality of Life in a Phase 4 Real-World Study of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis Authors: Jayme Heim, J...

Bimekizumab Maintenance of Response and Safety in Patients with Moderate-to-Severe Plaque Psoriasis: Results from the Open-Label...